GoodRx's core prescription savings platform is mature, with revenue flat at ~$200M per quarter and growth decelerating to -1.3% YoY in 2026Q2. The company maintains high gross margins (89.5% in 2026Q2) but faces structural pressures from PBM disintermediation ...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $0.08+0.4% vs $0.08 | $200M+3.7% vs $193M |
Q2 2026 May 6, 2026 | $0.07+0.0% vs $0.07 | $194M+4.6% vs $185M |
Q1 2026 Feb 25, 2026 | $0.09+0.0% vs $0.09 | $195M+0.8% vs $193M |
Q4 2025 Nov 4, 2025 | $0.08-11.1% vs $0.09 | $196M+1.4% vs $193M |
Prescription platform GoodRx has launched a new plan that covers a primary member and up to four dependents, including children, adult family members and pets, the company said in a Thursday (Sept. 3) press release.
GoodRx, a prescription drug savings site, announced on Thursday a family healthcare subscription for access to common medical services and over 250 medications, and it plans to launch the program as part of employer health benefits in 2027.
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the trusted platform for prescription access and affordability in the U.S., today launched the GoodRx Companion Family Plan, expanding its everyday healthcare subscription to the entire family, including pets. As widening coverage gaps and rising out-of-pocket costs leave households paying more for care, the new plan brings Companion's free and low-cost prescriptions and savings on common healthcare services together in one affordabl.
GoodRx has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. New offerings have contributed to GDRX's recent positive developments, but the stock's rapid appreciation reflects these improvements. I remain marginally more positive, yet GDRX still presents considerable risk, warranting a continued neutral rating.
Benchmark GDRX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for GoodRx Holdings, Inc. (GDRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.32 | $1.15B | 38.92 | 0.57% | 3.82% | 4.54% | — | |
| $28.39 | $6.33B | 55.67 | 59% | -5.51% | -30.03% | — | |
| $6.13 | $1.11B | -5.38 | -1.54% | -7.13% | -13.08% | — | |
| $7.60 | $142.61M | 28.15 | 18.78% | 4.66% | 3.6% | — | |
| $33.07 | $2.31B | -9.78 | — | — | -61.24% | — | |
| $26.57 | $4.97B | 27.11 | 13.05% | 25.48% | 16.95% | — |
GoodRx Holdings, Inc. (GDRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
GoodRx Holdings, Inc. (GDRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Aug 5, 2026·SEC
Jun 18, 2026·SEC
Get notified when GDRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GoodRx Holdings, Inc. (GDRX) stock FAQ — growth, dividends, profitability & financials explained
GoodRx Holdings, Inc. (GDRX) reported $785.2M in revenue for fiscal year 2025. This represents a 215% increase from $249.5M in 2018.
GoodRx Holdings, Inc. (GDRX) grew revenue by 0.6% over the past year. Growth has been modest.
Yes, GoodRx Holdings, Inc. (GDRX) is profitable, generating $16.2M in net income for fiscal year 2025 (3.8% net margin).
GoodRx Holdings, Inc. (GDRX) has a return on equity (ROE) of 4.5%. This is below average, suggesting room for improvement.
GoodRx Holdings, Inc. (GDRX) generated $145.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
